"The deal extends an investment pattern that has seen CZI commit substantial capital to AI-driven biology in recent months. Cellular Intelligence has raised more than $60m to date from investors including Khosla Ventures and the Chan Zuckerberg Initiative, Zuckerberg and Priscilla Chan's philanthropic vehicle. For Novo, the deal closes out one of the loose ends from last October's restructuring, which prioritised the company's obesity and diabetes franchises after demand for Wegovy and Ozempic continued to outpace supply."
Novo Nordisk transferred STEM-PD, an experimental allogeneic stem-cell-derived Parkinson’s therapy, to Cellular Intelligence. Novo will receive an equity stake and is eligible for future milestone payments and royalties, with financial terms not disclosed. STEM-PD is designed to replace dopamine-producing nerve cells lost in Parkinson’s disease and was previously in early clinical development at Novo. Novo discontinued the therapy in October after shutting down its cell-therapy unit during restructuring. Cellular Intelligence plans to use its proprietary AI platform to accelerate the program, scale manufacturing, and reduce production costs. Cellular Intelligence has raised more than $60 million from investors including Khosla Ventures and the Chan Zuckerberg Initiative.
Read at TNW | Health-Tech
Unable to calculate read time
Collection
[
|
...
]